References

• 2005Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits1,158 cited
• 2005National Institutes of Health State of the Science Conference Statement745 cited
• 2003Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults with Chronic Insomnia630 cited
• 2007The Direct and Indirect Costs of Untreated Insomnia in Adults in the United States403 cited
• 2000Zolpidem317 cited
• 2005A Review of the Evidence for the Efficacy and Safety of Trazodone in Insomnia308 cited
• 2004Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia294 cited
• 1997Management of Insomnia293 cited
• 2000Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia245 cited
• 1998Sleep Complaints in Community‐Dwelling Older Persons: Prevalence, Associated Factors, and Reported Causes233 cited
• 1998Psychotropic Medication Consumption Patterns in the UK General Population174 cited
• 2003Measuring outcomes in randomized clinical trials of insomnia treatments172 cited
• 2005Ramelteon (TAK-375), A Selective MT1/MT2-Receptor Agonist, Reduces Latency to Persistent Sleep in a Model of Transient Insomnia Related to a Novel Sleep Environment164 cited
• 2005Long-term use of sedative hypnotics in older patients with insomnia